November 2020 • PharmaTimes Magazine • 4-5
How pharma’s commitment to logistics has provided a supersonic slipstream to optimal performance
Why pharma needs to put data at the heart of its bid to support the NHS Reset
The question of artificial intelligence as an inventor – and what it means for drug discovery
What companies must do to maintain continuity of supply once the Brexit transition period ends
40.
Branching out
How pharma companies have improved how they engage with healthcare providers during COVID-19
42.
Patient Files: Spinal muscular atrophy (SMA)
Cheryl Yoder shares her family’s experiences with this rare, genetic disorder
44.
Appointments
Professor Sir Leszek Borysiewicz, chairman of Cancer Research UK, on the need for greater focus on cancer diagnosis